Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium (177Lu) vipivotide tetraxetan + lutetium (177Lu) DOTA-TATE + lutetium (177Lu) NeoB
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a **combination of three targeted radiopharmaceuticals**, each consisting of the radioactive isotope lutetium-177 (177Lu) linked via different chelation systems (DOTA, vipivotide tetraxetan, NeoB) to peptides that bind specific tumor-associated targets. **Lutetium (177Lu) DOTA-TATE** is a somatostatin analog targeting somatostatin receptor subtype 2 (SSTR2) on neuroendocrine tumor (NET) cells, allowing targeted beta radiation delivery[1][2][7]. **Lutetium (177Lu) vipivotide tetraxetan** is a radio-labeled ligand specifically targeting prostate-specific membrane antigen (PSMA), overwhelmingly expressed in prostate cancer cells. **Lutetium (177Lu) NeoB** is a gastrin-releasing peptide receptor (GRPR) antagonist, targeting cancers like prostate and breast that express GRPR. All three agents function by delivering cytotoxic radiation to specific cancer cells, improving tumor control in appropriately selected patients.
- Brand names
- Lutathera
- Other names
- 177Lu-DOTATATE177Lu vipivotide tetraxetan177Lu NeoB
02
Targets
GRPR (Gastrin-releasing peptide receptor)PSMA (Prostate-specific membrane antigen)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on lutetium (177Lu) vipivotide tetraxetan + lutetium (177Lu) DOTA-TATE + lutetium (177Lu) NeoB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium (177Lu) vipivotide tetraxetan + lutetium (177Lu) DOTA-TATE + lutetium (177Lu) NeoB.